How the rush to decriminalize magic mushrooms could hurt psychedelic drug research

mushrooms x
Image: Fred Lucas/Daily Signal

Welcome to a murky new front in the war to bring psychedelics out of the shadows and into both legal recreational use and professional drug-assisted therapy. In recent years researchers have shown that psychedelics like mushrooms and LSD appear to treat a range of disorders, including depression and PTSD. The paradigm is so promising, in fact, that the FDA has granted MDMA breakthrough status in phase 3 trials, thus fast-tracking the approval process. Psilocybin itself is undergoing two separate clinical trials.

Meanwhile, the psilocybin decriminalization movement is snowballing at an incredible clip. [June 4] the Oakland, California, city council voted unanimously to decriminalize a range of psychedelic plants, including mushrooms and cacti.

ADVERTISEMENT

The concern, as Michael Pollan—author of How to Change Your Mind, a recent book on psychedelic science—expressed in a piece in The New York Times last month, is this: The accelerating movement to decriminalize psilocybin risks a political backlash, which could derail that promising research. “It would be a shame if the public is pushed to make premature decisions about psychedelics before the researchers have completed their work,” he writes.

Read full, original post: The heady, thorny journey to decriminalize magic mushrooms

Related article:  Why genealogy tests will 'send a lot more people to jail' in 2019
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend